[1]黄 维.小儿定喘口服液联合吸入性布地奈德治疗小儿支气管肺炎的临床疗效及对炎性水平的影响[J].医学信息,2024,37(23):121-124.[doi:10.3969/j.issn.1006-1959.2024.23.029]
　HUANG Wei.Clinical Efficacy of Xiao′er Dingchuan Oral Liquid Combined with Inhaled Budesonide in the Treatment of Bronchopneumonia in Children and its Effect on Inflammatory Level[J].Journal of Medical Information,2024,37(23):121-124.[doi:10.3969/j.issn.1006-1959.2024.23.029]
点击复制

小儿定喘口服液联合吸入性布地奈德治疗小儿支气管肺炎的临床疗效及对炎性水平的影响()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年23期
页码:
121-124
栏目:
药物与临床
出版日期:
2024-12-01

文章信息/Info

Title:
Clinical Efficacy of Xiao′er Dingchuan Oral Liquid Combined with Inhaled Budesonide in the Treatment of Bronchopneumonia in Children and its Effect on Inflammatory Level
文章编号:
1006-1959（2024）23-0121-04
作者:
黄 维
上栗县妇幼保健院儿科，江西 上栗 337009
Author(s):
HUANG Wei
Department of Pediatrics,Shangli County Maternal and Child Health Hospital,Shangli 337009,Jiangxi,China
关键词:
小儿定喘口服液; 吸入性布地奈德; 支气管肺炎; 炎性水平
Keywords:
Xiao′er Dingchuan oral liquid; Inhalational budesonide; Bronchopneumonia; Inflammatory level
分类号:
R725.6
DOI:
10.3969/j.issn.1006-1959.2024.23.029
文献标志码:
A
摘要:
目的 观察小儿定喘口服液联合吸入性布地奈德治疗小儿支气管肺炎的临床疗效及对炎性水平的影响。方法 选取2022年8月-2023年8月我院诊治的64例小儿支气管肺炎患儿为研究对象，采用随机数字表法分为对照组和观察组，各组32例。对照组采用吸入性布地奈德治疗，观察组在对照组基础上联合小儿定喘口服液治疗，比较两组临床疗效、炎性因子[白细胞计数（WBC）、C反应蛋白（CRP）、中性粒细胞]水平、临床症状（喘息、发热、咳嗽、肺部啰音）缓解时间、呼吸道症状（咳嗽、咳痰、喘鸣音）评分、不良反应发生率。结果 观察组治疗总有效率为96.88%，高于对照组的81.25%（P＜0.05）；两组治疗后WBC、CRP、中性粒细胞水平均低于治疗前，且观察组低于对照组（P＜0.05）；观察组喘息、发热、咳嗽、肺部啰音缓解时间均短于对照组（P＜0.05）；两组治疗后咳嗽、咳痰、喘鸣音评分均低于治疗前，且观察组低于对照组（P＜0.05）；观察组不良反应发生率与对照组比较，差异无统计学意义（P＞0.05）。结论 小儿定喘口服液联合吸入性布地奈德治疗可提高小儿支气管肺炎治疗效果，减轻其临床症状，降低炎性因子水平，且不会增加不良反应发生率，是一种有效的治疗方案。
Abstract:
Objective To observe the clinical efficacy of Xiao′er Dingchuan oral liquid combined with inhaled budesonide in the treatment of bronchopneumonia in children and its effect on inflammatory level.Methods A total of 64 children with bronchopneumonia diagnosed and treated in our hospital from August 2022 to August 2023 were selected as the research objects. They were divided into control group and observation group by random number table method, with 32 children in each group. The control group was treated with inhaled budesonide, and the observation group was treated with Xiao′er Dingchuan oral liquid on the basis of the control group. The clinical efficacy, inflammatory factors [white blood cell count (WBC), C-reactive protein (CRP), neutrophils] levels, clinical symptoms (wheezing, fever, cough, pulmonary rales) remission time, respiratory symptoms (cough, sputum, wheezing) scores, and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 96.88%, which was higher than 81.25% in the control group (P<0.05). After treatment, the levels of WBC, CRP and neutrophils in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05). The remission time of wheezing, fever, cough and pulmonary rales in the observation group were shorter than those in the control group (P<0.05). After treatment, the scores of cough, expectoration and wheezing in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the observation group and the control group (P>0.05).Conclusion Xiao′er Dingchuan oral liquid combined with inhaled budesonide can improve the therapeutic effect of bronchopneumonia in children, reduce its clinical symptoms, reduce the level of inflammatory factors, and will not increase the incidence of adverse reactions. It is an effective treatment plan.

参考文献/References:

[1]Dangor Z,Lala S,Verwey C,et al.Bronchiolitis versus bronchopneumonia: navigating antibiotic use within the LRTI spectrum[J].S Afr Med J,2023,113(6):20-23.[2]赵霞,秦艳虹,王有鹏,等.儿童哮喘中医诊疗指南(修订)[J].南京中医药大学学报,2022,38(6):476-482. [3]Huang K,Yang T,Xu J,et al.Prevalence,risk factors,and management of asthma in China:a national cross-sectional study[J].Lancet,2019,394(10196):407-418. [4]胡博,王小稳.小儿定喘口服液联合氨茶碱治疗小儿支气管哮喘的临床疗效[J].中国合理用药探索,2019,16(11):25-27,31. [5]中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.支气管哮喘基层诊疗指南(2018)年[J].中华全科医师杂志,2018,17(10):751-762.[6]王爽.止哮汤合哮咳喘胶囊治疗小儿支气管哮喘100例临床疗效观察[D].长春:长春中医药大学,2018. [7]陈燕燕.喜炎平注射液联合特布他林、布地奈德雾化吸入治疗儿童支气管肺炎的效果及对炎症指标的影响[J].儿科药学杂志,2017,23(8):29-32.[8]邓文华,甘小利,刘海龙.小儿肺热咳喘颗粒对哮喘患儿血清炎症因子水平及肺功能指标的影响[J].江西医药,2021,56(6):846-847,853. [9]方草,乐丽君.小儿肺热咳喘颗粒治疗小儿支气管哮喘的疗效分析[J].湖北科技学院学报(医学版),2022,36(1):45-48. [10]Bach LM,Rubak S,Holm-Weber A,et al.Risk Factors for Non-Adherence to Inhaled Corticosteroids in Preschool Children with Asthma[J].Children(Basel),2022,10(1):43.[11]卢淑华.影响儿科支气管肺炎严重程度的因素分析[J]. 医学理论与实践,2020,33(3):452-453.[12]刘娟.硫酸沙丁胺醇联合不同剂量布地奈德混悬液雾化吸入治疗小儿支气管哮喘合并肺炎支原体感染的临床观察[J].中国合理用药探索,2020,17(1):68-72.[13]闫秀侠.青金栀汤联合布地奈德、硫酸沙丁胺醇雾化吸入对急性毛细支气管炎患儿肺功能及炎症水平的影响[J].河南医学研究,2020,29(13):2421-2423.[14]伍祥胡,梁霞,凌洁萍.异丙托溴铵溶液、沙丁胺醇、布地奈德混悬液联合雾化吸入治疗小儿毛细支气管炎的效果研究[J].解放军预防医学杂志,2019,37(4):114-115.[15]夏庆,王来栓,徐小静.小儿定喘口服液联合阿奇霉素治疗40例小儿喘息性支气管炎的临床疗效观察[J].贵州医药,2017,41(5):512-513.[16]赵晓琴,邢莎莎.布地奈德联合沙丁胺醇治疗支气管哮喘疗效的研究[J].山西医药杂志,2019,48(6):699-700.[17]唐建军,肖刚,冯圣芳,等.布地奈德混悬液联合硫酸沙丁胺醇雾化吸入治疗小儿毛支气管炎的临床疗效[J].临床合理用药杂志,2019,12(3):1-2.[18]杨绍心,员丽,张卫星.小儿定喘口服液联合布地奈德治疗支气管哮喘患儿急性发作的研究[J].实用中医内科杂志,2021,35(12):118-121. [19]刘常.布地奈德联合特布他林雾化吸入治疗儿童支原体肺炎的疗效[J].医学信息,2019,32(23):140-141.[20]颜琳琳.布地奈德、特布他林、异丙托溴铵联合雾化吸入辅助治疗小儿肺炎支原体肺炎的临床效果分析[J].基层医学论坛,2019,23(34):4918-4919.

更新日期/Last Update: 1900-01-01